Prelude Capital Management’s LENZ Therapeutics LENZ Stock Holding History

Prelude Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$147K	Sell	16,072 -154,152	-91%	-$2.17M	0.01%	981
2025 Q4	$2.72M	Buy	+170,224	New	+$4.96M	0.2%	108
2024 Q1	–	Sell	-4,083	Closed	-$74.9K	–	1560
2023 Q4	$74.9K	Sell	4,083 -43	-1%	-$710	0.01%	1050
2023 Q3	$71.6K	Sell	4,126 -1,665	-29%	-$29K	﹤0.01%	1018
2023 Q2	$105K	Buy	5,791 +1,205	+26%	+$24.1K	0.01%	926
2023 Q1	$78.6K	Sell	4,586 -300	-6%	-$4.85K	﹤0.01%	975
2022 Q4	$114K	Buy	4,886 +186	+4%	+$4.31K	0.01%	1060
2022 Q3	$104K	Buy	4,700 +1,206	+35%	+$28.7K	﹤0.01%	1163
2022 Q2	$67K	Buy	+3,494	New	+$77.9K	﹤0.01%	1464

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Prelude Capital Management's LENZ Position: Q1 2026 in Review

Prelude Capital Management reduced its LENZ Therapeutics (LENZ) stake by 91% in Q1 2026, selling an estimated $2.17M and leaving 16,072 shares worth $147K. The position accounts for 0.01% of the portfolio, ranked #981.

Prelude Capital Management first reported a position in LENZ in Q2 2022 and has held it in 9 quarters since. The position peaked at $2.72M in Q4 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

Prelude Capital Management held 16,072 shares of LENZ Therapeutics worth $147K as of Q1 2026.
Prelude Capital Management sold 154,152 LENZ Therapeutics shares in Q1 2026, an estimated $2.17M.
LENZ Therapeutics made up 0.01% of Prelude Capital Management's portfolio in Q1 2026, its #981 holding.
Prelude Capital Management first reported a position in LENZ Therapeutics in Q2 2022 and has held it in 9 quarters since.
Prelude Capital Management's LENZ Therapeutics position peaked at $2.72M in Q4 2025.
145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.